Gilead Sciences, Inc. (NASDAQ:GOLD) is among the the most profitable health stocks to buy. On January 26, UBS raised the price objective on Gilead Sciences, Inc. (NASDAQ:GILD) from $145 to $155 and maintained a buy rating, according to TheFly. Slightly below the consensus 1-year high price target, the revised target implies almost 12% upside.

From attractive valuations and light positioning to supporting drug overpricing and sustained pharma-led M&A activity, there are many reasons to believe in the strong performance of the US pharmaceuticals and biotech group, the analyst noted. UBS noted that while there are concerns about conservative guidance, especially after the recent rally, the financial valuations of big pharma and biotech are expected to continue positive cash flows into the sector.

Copyright: dolgachov / 123RF Stock Photo

On the same day, BMO Capital also raised its target on Gilead Sciences, Inc. (NASDAQ:GILD) to $150 from $135 and reiterated an outperform rating on the stock. While highlighting the launch of Yeztugo, which achieved $150 million in FY25 sales, the company cited strong momentum in the company’s HIV business.

​Gilead Sciences, Inc. (NASDAQ:GILD) is a California-based biopharmaceutical company specializing in medicines targeting unmet needs. Founded in 1987, the company offers a range of products as solutions for HIV/AIDS, COVID-19, viral hepatitis, oncology, pulmonary arterial hypertension and serious invasive fungal infections.

While we recognize GILD’s potential as an investment, we believe some AI stocks offer greater upside potential and less downside risk. If you’re looking for an extremely undervalued AI stock that will also benefit significantly from Trump-era tariffs and the onshoring trend, check out our free report on the best short term AI stock.

READ THE FOLLOWING: The best and worst Dow stocks for the next 12 months i 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: no.